News
Investing.com — BMO Capital Markets degradó la calificación de Novo Nordisk (NYSE: NVO) a "Market Perform" desde "Outperform" ...
Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback